Aflac Earnings Call: Strong Sales, Cautious Outlook

AFLAC Incorporated ((AFL)) has held its Q4 earnings call. Read on for the main highlights of the call.

Aflac Balances Strong Sales and Capital Returns With Emerging Headwinds in Latest Earnings Call

Aflac’s latest earnings call conveyed a cautiously stable outlook: management highlighted strong sales momentum in Japan and the U.S., robust capital returns, and a very solid capital and liquidity profile, but tempered that optimism with clear acknowledgment of near-term earnings pressures. Declining underlying earned premiums in Japan, rising benefit ratios and claims pressure in the U.S., softer investment income, and some corporate credit losses all weighed on profitability, keeping earnings growth modest despite an aggressive capital return program.

Quarterly and Full-Year Earnings: Solid but Not Spectacular

Aflac reported fourth-quarter net EPS of $2.64 and adjusted EPS of $1.57, with full-year 2025 net EPS of $6.82 and adjusted EPS of $7.49. Adjusted EPS in Q4 grew just 0.6% year over year on a currency-neutral basis, underscoring limited near-term earnings leverage. Adjusted book value per share, excluding currency, rose a modest 0.5%, reflecting stability rather than breakout performance. The figures show a company generating dependable earnings but contending with headwinds that cap upside in the short term.

Japan Sales Surge on New Products

Aflac Japan delivered standout top-line momentum, with sales up 15.7% in Q4 and 16% for the year. The Miraito cancer product was the star, driving a 35.6% increase in cancer product sales and signaling strong demand for newer protection offerings. The newly launched Anshin Palette medical product saw encouraging early uptake after its late-December rollout, and the repriced Tsumitasu product is supporting deeper penetration among younger customers. The strength in new product adoption positions Aflac Japan for future growth, even if it takes time for these sales to fully manifest in earned premiums.

High Persistency Supports Japan’s Long-Term Book

Japan’s premium persistency remained exceptionally strong at 93.1% for the year, highlighting the stickiness of Aflac’s in-force business. This high retention rate provides long-term earnings visibility and stability, even as the company introduces and reprices products. However, the same persistency also means that new business takes longer to tilt overall premium trends, a dynamic management explicitly acknowledged when discussing the timing of earned premium inflection.

U.S. New Sales and Premiums Maintain Growth Trajectory

In the U.S., Aflac generated nearly $1.6 billion in new sales in 2025, with more than one-third of that coming in the fourth quarter alone. Net earned premiums grew about 2.9% for the year, with Q4 U.S. net earned premiums up 4%, supported by strong premium persistency at 79.2%. The U.S. operation is clearly growing, but at a measured pace, balancing mature-core voluntary lines with expansion into newer segments and channels.

Group and New Channels Power U.S. Diversification

Aflac’s strategic shift toward group products and alternative distribution channels in the U.S. is gaining traction. Network dental sales surged 48.8% year over year, while life, absence and disability combined grew 11.3%. Direct-to-consumer business grew 10.5%, reflecting the benefits of brand recognition and digital outreach. Group-focused initiatives now account for roughly 20% of new U.S. sales, indicating that Aflac’s diversification strategy is becoming a more meaningful earnings contributor over time.

Record Capital Returns and Higher Dividend

The call underscored a shareholder-friendly capital allocation stance. In 2025, Aflac deployed a record $3.5 billion on share repurchases, retiring approximately 33 million shares, and paid $1.2 billion in dividends, returning about $4.8 billion to shareholders in total. In the fourth quarter alone, buybacks totaled $800 million and dividends $303 million. The board approved a 5.2% increase in the Q1 2026 dividend, reinforcing management’s confidence in ongoing cash-generation capacity despite near-term operating pressures.

Capital and Liquidity Remain a Core Strength

Aflac emphasized its strong balance sheet and funding flexibility. The company enhanced liquidity through two off-balance-sheet PCAP structures providing $2.0 billion of undrawn capacity. Holding-company unencumbered liquidity stands at $4.1 billion, around $3.1 billion above the stated minimum, while adjusted leverage is 21.4%, comfortably within the 20–25% target range. Regulatory capital metrics are robust, with a solvency margin ratio above 970%, an estimated ESR around 253%, and combined RBC near 575%. These figures reinforce that Aflac has ample capacity to absorb volatility and continue disciplined capital deployment.

Investment Portfolio Shows Resilience With Limited Credit Stress

Investment and credit performance remained generally solid. Aflac reported no quarterly charge-offs in commercial real estate and no foreclosures, a notable positive given broader concerns in that asset class. The investment portfolio continued to deliver healthy net investment income, supported by diversification and limited exposure to more volatile sectors such as software (around 1.5% of the portfolio). The middle-market loan book is diversified, though not immune to stress, as reflected in some targeted charge-offs.

Profitability Slips as U.S. Margins Compress

On profitability, Aflac posted an adjusted ROE of 11.7%, or 14.5% excluding foreign-exchange remeasurement, signaling solid but not elevated returns. Japan’s pretax margin remained strong at 31.3%, down only 30 basis points from last year, while the U.S. pretax margin fell to 17.4%, a decline of 230 basis points from a strong prior-year period. The U.S. margin compression reflects higher benefit ratios and rising claims intensity, highlighting that the U.S. business is currently bearing more of the operating pressure than Japan.

Japan’s Underlying Premiums Under Pressure

Despite robust new business, Japan net earned premiums declined 1.9% year over year in Q4 (in yen terms), and underlying earned premiums—excluding certain items such as DPL, paid-up policies and reinsurance—were down 1.2%. Management expects underlying earned premiums in Japan to decline 1% to 2% in 2026, reflecting a large, mature in-force block and high persistency that slow the translation of new sales into overall premium growth. This creates a near-term headwind for top-line earnings contribution from Japan.

U.S. Claims Trends Drive Higher Benefit Ratios

In the U.S., the total benefit ratio rose to 48.6% in Q4, up 230 basis points from a year earlier. This increase was driven by prior-year endorsements, elevated claims on the individual voluntary block, and higher benefit ratios in group life and disability. These trends directly pressured U.S. pretax margins and illustrate a more challenging claims environment, which investors will watch closely to assess whether it is cyclical or structural.

Investment Income Softens Amid Rate and Mix Shifts

Adjusted net investment income declined in both major segments. In Japan, net investment income fell 3.9% in yen terms, mainly due to lower floating-rate income on U.S. dollar assets and weaker variable investment income. In the U.S., adjusted net investment income was down 2.8%, reflecting a smaller floating-rate asset base and lower rates. Variable investment income came in about $12 million below long-term expectations for the quarter, weighing on overall earnings and underscoring sensitivity to market and rate dynamics.

Japan Expense Ratio Rises With Sales Push

Japan’s expense ratio increased to 22% in Q4, up 120 basis points year over year, primarily due to elevated sales promotion expenses tied to strong new product launches. While these investments support growth in Miraito, Anshin Palette and other offerings, they temporarily pressure margins. Management framed this as a strategic choice to capture share and build a pipeline of future earnings, even at the cost of higher near-term operating expenses.

Corporate Losses and Targeted Loan Charge-Offs

At the Corporate and Other level, Aflac recorded an adjusted pretax loss of $31 million in Q4. Tax credit investments reduced net investment income by $43 million in the quarter, although they still delivered a net earnings benefit after tax. The company also recognized $22 million of charge-offs on first-lien senior secured middle-market loans and a $3 million valuation allowance on mortgage loans. While modest in the context of Aflac’s overall balance sheet, these items highlight pockets of credit normalization and the earnings noise created by tax-oriented investments.

Slow Translation of Strong Japan Sales Into Premium Growth

Management emphasized that, despite strong new business momentum in Japan, high persistency and the size of the existing in-force book mean that lapses will still exceed new sales in 2026. As a result, underlying earned premiums are expected to continue declining in the near term, delaying any positive inflection in reported earned premium growth. For investors, this means that Japan’s strong sales narrative will take time to show up as sustained top-line and earnings expansion.

Only Modest EPS Growth Despite Robust Activity

The combination of higher claims, softer investment income, and elevated expenses meant that adjusted EPS growth in Q4, excluding currency, was only 0.6% year over year. This relatively modest increase stands in contrast to the strong sales numbers and sizable capital returns, illustrating that much of the current activity is either long-dated in its impact (as in Japan new business) or offset by margin pressure elsewhere. Near term, this dynamic caps upside to earnings momentum even as the company invests for future growth.

Reserves and Remeasurements Complicate Underlying Trend Analysis

Aflac’s reported benefit ratios were aided by reserve remeasurement gains, which added roughly 110 basis points of favorability in Japan and about 140 basis points in the U.S. These gains help earnings in the quarter but can obscure underlying claims and cost trends. Investors parsing the results need to adjust for these one-off benefits to get a clearer sense of core claims experience and margin trajectory.

Product Lapses and Reissues Add Volatility

New product introductions, including Miraito and the new medical product, led to elevated lapse and reissue activity in Japan, as policyholders move from older offerings into updated designs. While this activity is within management’s expectations and strategically desired, it increases reported lapsation and releases reserves, which can add volatility to GAAP benefit ratios and make quarter-to-quarter comparisons more complex. Over time, the shift should align the book with more modern, competitively priced products, but it complicates short-term optics.

Forward Guidance: Cautious Growth With Strong Capital Backing

Looking ahead to 2026, management largely reaffirmed its prior multi-year guidance ranges, signaling confidence in the underlying trajectory despite near-term pressure. In Japan, underlying earned premiums are expected to decline 1% to 2%, with an expense ratio of 20%–23%, a benefit ratio of 60%–63%, and a pretax margin of 33%–36%, underscoring continued profitability even amid modest top-line erosion. In the U.S., net earned premium growth is projected at the lower end of the 3%–6% range, with a benefit ratio of 48%–52%, an expense ratio of 36%–39%, and a pretax margin of 17%–20%. Management also reiterated its strong capital and liquidity stance—adjusted leverage at 21.4% within its 20%–25% target, high solvency and RBC metrics, $4.1 billion of holding-company liquidity well above the new $1.0 billion minimum, and an undrawn PCAP facility—while confirming ongoing tactical capital deployment through buybacks and a higher dividend.

In summary, Aflac’s earnings call painted a picture of a financially strong insurer using its capital flexibility to reward shareholders and invest into attractive growth initiatives, particularly in Japan and U.S. group lines, while navigating a patch of earnings headwinds. Sales momentum is robust and balance sheet strength is clear, but declining underlying premiums in Japan, higher U.S. claims, and softer investment income are dampening near-term EPS growth. For investors, the story is one of stable fundamentals, disciplined capital management, and a long-term growth strategy, set against a backdrop of modest short-term earnings pressure and a cautious yet confident management tone.